Date: 12/11/2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

Scrip Code: 544535

Sub: Intimation under Regulation 30 of SEBI (LODR)-Press Release on BharatRohan Achieves Technology Milestone in Hyperspectral Imaging for Pharmaceutical Quality Screening; Engaged in Discussions with Regulatory Authorities

Dear Sir/Maam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed a copy of the press release titled *"BharatRohan Achieves Technology Milestone in Hyperspectral Imaging for Pharmaceutical Quality Screening; Engaged in Discussions with Regulatory Authorities"*, announcing that the Company has achieved a significant internal technology milestone in applying its proprietary hyperspectral imaging platform to pharmaceutical quality screening.

Kindly take the same on your record,
Thanking You.

For BharatRohan Airborne Innovations Limited

AAKANSHA SINGH
Digitally signed by AAKANSHA SINGH
Date: 2026.11.12 19:52:32 +05'30'

Aakansha Singh
Company Secretary & Compliance Officer

Encl: As Above

BharatRohan Achieves Technology Milestone in Hyperspectral Imaging for Pharmaceutical Quality Screening; Engaged in Discussions with Regulatory Authorities

Company highlights long term commercial potential, contingent on further validation, as it advances a new application of its imaging platform

Gurugram, India; November 12, 2026: BharatRohan Airborne Innovations Limited ("BharatRohan" or "the Company"), a hyperspectral imaging technology company, today announced that it has achieved a significant internal technology milestone in applying its proprietary hyperspectral imaging platform to pharmaceutical quality screening. In controlled proof-of-concept testing, the Company's imaging system demonstrated the ability to non-destructively differentiate genuine pharmaceutical tablets from adulterated or substandard samples by capturing and analysing spectral signatures across the visible and near-infrared portions of the spectrum.

This represents an extension of the Company's existing hyperspectral imaging expertise, developed and commercially deployed in precision agriculture, into pharmaceutical quality assurance and anti-counterfeiting, opening a new addressable market for the Company.

Commenting on the Milestone, Mr. Amandeep Panwar, Chairman and Managing Director of BharatRohan Airbourne Innovations Limited. said:

"This milestone reflects years of work extending our hyperspectral imaging expertise from agriculture into an entirely new domain: pharmaceutical quality and anti-counterfeiting. We believe non-destructive, image-based screening can meaningfully complement existing laboratory testing methods used by regulators and industry today. We are committed to a rigorous, evidence-led path toward validating this technology with the appropriate scientific and regulatory authorities before pursuing any commercial deployment."

Technology and Internal Validation

In internal proof-of-concept testing, the Company's hyperspectral imaging system distinguished a widely used analgesic-antipyretic tablet from a common adulterant on a pixel-by-pixel basis without damaging or consuming the sample. The Company has since extended this testing across a broader panel of widely used medicines, including analgesic, macrolide antibiotic and anti-diabetic tablets, as well as fixed-dose combinations (anti-allergy/anti-asthma combinations and a penicillin plus beta-lactamase-inhibitor antibiotic combination), examining dosage variation, underdosing and adulteration with common pharmaceutical excipients.

Across the panel, genuine material and adulterants were mixed by weight at genuine-to-adulterant ratios of 100:0, 90:10, 70:30, 50:50 and 0:100 (pure adulterant). The samples were imaged as a batch. The adulterants tested included calcium carbonate (chalk), starch, talc, microcrystalline cellulose, gypsum and lactose. In fixed-dose combination tablets adulterated at 30% by weight with talc, corn starch or chalk, each adulterant produced a distinct spectral signature that distinguished it from the genuine product and from the other adulterants.

In a second fixed-dose combination, the loss of a spectral feature associated with an active ingredient provided another possible indicator of dilution in adulterated samples. The Company is working to confirm this finding.

Further testing on an antibiotic tablet showed that coated, uncoated and generic formulations, as well as a calcium carbonate adulterant, could each be distinguished by their spectral response, with film coating and formulation differences producing distinguishable spectral effects. Separately, analgesic tablets from different manufacturers showed highly similar spectral profiles at the active-ingredient level, suggesting that spectral variation among genuine products from different manufacturers may be small. The Company is continuing to evaluate this finding.

Early internal testing also indicates that the system's spectral signal shifts in proportion to the degree of adulteration in a mixed sample, suggesting the potential to estimate adulterant content semi-quantitatively and classify samples as genuine or non-genuine. The Company considers this an early and promising finding rather than a validated quantitative method and is working to expand the sample set and strengthen the statistical evidence needed to support the finding.

These results are based on controlled internal testing using a limited sample set and have not yet been independently validated, peer-reviewed, or assessed by any regulatory or pharmacopoeial authority. Before drawing conclusions about real-world performance, the Company is continuing to expand its testing to assess the effects of tablet coatings and packaging and to cover a wider range of formulations.

Engagement with Regulatory and Scientific Authorities

The Company is currently engaged in discussions with multiple regulatory and scientific authorities in India's pharmaceutical quality ecosystem to explore pathways for validating and potentially piloting this technology. BharatRohan is not disclosing the specific nature, status, or content of these discussions at this time. There can be no assurance that any such engagement will result in a formal pilot, validation, sample-testing arrangement, or commercial relationship of any kind, or that it will proceed on any particular timeline.

Global Footprint

BharatRohan operates a research and development subsidiary, GroeiGids B.V., in the Netherlands. Established in October 2024, the subsidiary focuses on advancing hyperspectral imaging technology and its applications. The subsidiary gives the Company a base in Europe from which to engage with European pharmaceutical and agri-technology stakeholders as it evaluates international applications of this technology, alongside its ongoing engagement with authorities in India.

Collaboration and Intellectual Property

BharatRohan welcomes dialogue with pharmaceutical manufacturers, contract testing laboratories, distributors and technology partners interested in exploring pilot evaluations of the technology, subject to appropriate confidentiality and collaboration agreements. Technical details of the Company's methods and data are available to relevant parties on a confidential basis and are not included in this release.

Potential Commercial Opportunity

The Company believes that, if this technology is successfully validated and adopted, non-destructive, imaging-based pharmaceutical quality screening could represent a significant long-term commercial opportunity, both in India and internationally. Realising this opportunity depends on successful technical and regulatory validation, pharmacopoeial or regulatory acceptance, and commercial adoption by testing laboratories, regulators or industry. None of these outcomes is assured.

Based on preliminary internal analysis, and solely for illustrative purposes, the Company estimates the following (these estimates are unaudited, have not been independently verified and are subject to revision):

Market measure	Global (illustrative)	India (illustrative)
Total Addressable Market (TAM)	~US$0.8–1.8 billion	~US$100–200 million
Serviceable Addressable Market (SAM)	~US$80–350 million	~US$15–50 million
Serviceable Obtainable Market (SOM), 3-year horizon	~US$1.5–8 million	~US$1–5 million

These estimates consider potential use by pharmaceutical manufacturers, marketing authorisation holders that outsource production to third-party or contract manufacturers, contract manufacturing organisations, testing laboratories and regulators. For context, third-party research estimates the global infrared spectroscopy market at approximately US$1.4 billion in 2025, with pharmaceutical and biopharmaceutical users accounting for roughly 40% of revenue (Mordor Intelligence); the global contract development and manufacturing market at approximately US$243 billion in 2024 (Fortune Business Insights, as cited by India Briefing).

The Government of India reports approximately 10,500 pharmaceutical manufacturing units in the country (Press Information Bureau). TAM and SAM are expressed on an annual-equivalent basis, with system costs spread over an assumed five-year life. SOM represents cumulative revenue over three years. The pricing, site counts and adoption rates used are internal assumptions.

These figures are preliminary, internally generated, bottom-up estimates based on the Company's own assumptions about market structure, adoption rates, and deployment economics. They are not derived from third-party market research, have not been audited or independently verified, and do not constitute a forecast, projection, guidance, or guarantee of future revenue. They should be read only as an illustration of the potential long-term opportunity if and when this technology is successfully validated and commercialized, not as a statement about current or near-term financial performance. Actual outcomes may differ materially, or this opportunity may not be realised at all.

About BharatRohan

BharatRohan Airborne Innovations Limited is an India-based advanced technology company specialising in hyperspectral imaging and AI-powered analytics. The Company develops innovative technology solutions that enable deeper insights, early detection, and data-driven decision-making across industries.

With established commercial applications in drone-based precision agriculture and the food supply chain, BharatRohan is expanding its technology applications across pharmaceuticals, solar energy, asset monitoring, infrastructure, freight route simulation, commercial plantations, and other sectors.

The Company operates GroeiGids B.V., its research and development subsidiary in the Netherlands, established in October 2024. Through GroeiGids B.V., it also owns BharatRohan INC., a Delaware-incorporated subsidiary focused on building a technology-enabled, farm-to-jar spice and ingredient platform for the U.S. market.

This press release contains forward-looking statements, including statements regarding the Company's technology, its potential applications, the outcome and timing of engagement with regulatory and scientific authorities, and the size and realisation of any future market opportunity. These statements are based on current expectations and assumptions and are subject to risks and uncertainties, including the outcome of ongoing or future discussions with regulatory and scientific authorities; whether the Company's technology is successfully validated, including against pharmacopoeial or other regulatory standards; market and customer acceptance; competitive developments; and other factors beyond the Company's control. Actual results, outcomes, and timelines may differ materially from those expressed or implied in this release. The Company undertakes no obligation to publicly update or revise any forward-looking statement, except as required by applicable law or stock exchange regulations.

This announcement does not constitute, and should not be construed as, investment advice or a solicitation to buy or sell any securities

For further information, please contact

BharatRohan Airborne Innovations
Ms. Aakansha Singh
Company Secretary
investors@bharatrohan.in

Churchgate Partners
Simran Malhotra / Soham Arora
+91 99454 72589
bharatrohan@churchgatepartners.com